Now showing items 1-2 of 2

    • CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900 

      Gönen, M; Sun, Z; Figueroa, ME; Patel, JP; Abdel-Wahab, O; Racevskis, J; Ketterling, RP; Fernandez, H; Rowe, JM; Tallman, MS; Melnick, A; Levine, RL; Paietta, E (College of Biological and Physical Sciences ,Department of physics, 2012)
      We determined the prognostic relevance of CD25 (IL-2 receptor-α) expression in 657 patients (≤ 60 years) with de novo acute myeloid leukemia (AML) treated in the Eastern Cooperative Oncology Group trial, E1900. We identified ...
    • Prognostic relevance of integrated genetic profiling in acute myeloid leukemia 

      Huberman, K; Aminova, O; Thomas, S; Dolgalev, L; Van Vlierberghe, P; Racevskis, J; Sun, Z; Fernandez, H; Figueroa, ME; Gönen, M; Patel, JP; Cheng, J; van den Brink, MR; Litzow, M; Gallagher, RE; Ketterling, RP; Viale, A; Socci, ND; Heguy, A; Cherry, A; Vance, G; Higgins, RR; Levine, RL; Abdel-Wahab, O; Melnick, A; Tallman, MS; Paietta, E; Ferrando, A; Luger, S; Rowe, JM; Lazarus, HM (College of Biological and Physical Sciences ,Department of physics, 2012)
      BACKGROUND: Acute myeloid leukemia (AML) is a heterogeneous disease with respect to presentation and clinical outcome. The prognostic value of recently identified somatic mutations has not been systematically evaluated ...